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Background:  Antigen  detection  tests  have  been  the  most  common  diagnostic  assay  used  to  detect  and  diag-
nose respiratory  syncytial  virus  (RSV).  The  utility  and  increased  sensitivity  of  polymerase  chain  reaction
(PCR)  tests  have  been  reported;  however,  their  use  in US  hospital  laboratories  is not  well  characterized.
Objective:  To  describe  changes  in RSV  test  types  used  by  US  hospital-afﬁliated  laboratories,  focusing  on
PCR  testing  prevalence.
Study design:  Data  were  collected  from 480  to 666  laboratories  each  RSV  season  (2007–2008  through
2010–2011)  across  50  states,  the  District  of  Columbia,  and  Puerto  Rico.  A  descriptive  analysis  was  con-
ducted  using  this  convenience  sample  of  RSV  tests  conducted  from  November  to  April each  season.
Total  numbers  and  types  of  RSV tests  performed  were  reported  weekly  and  weekly  proportions  by test
type  were  calculated.  Kendall   rank  correlation  was  used  to  quantify  associations  between  time  and
proportions  of  each  test  type.
Results:  PCR  tests  accounted  for 2%, 3%,  16%,  and  21%  of  weekly  tests  (total  range,  381,068–481,654  over  4
seasons)  conducted  each  season  from  2007  to 2011,  respectively.  The  proportion  of laboratories  reporting
≥1  PCR  tests  was  4%,  5%,  10%, and 16%,  respectively.  Decreases  in  antigen  testing  and  viral  culture  were
similarly  observed.
Conclusions:  Although  antigen  detection  was  the  predominant  test  type  reported  in  the  sample  of  US  hos-
pital laboratories  for  RSV  testing,  PCR  use  increased  to  >20%  of  tests  reported.  These  results  demonstrate
the  increasing  contribution  of  PCR  to RSV surveillance.  RSV  surveillance  systems  relying  solely  on  antigen
detection  results  will  not  capture  an  increasing  proportion  of  RSV  test  results.Abbreviations: CDC, US Centers for Disease Control and Prevention; DC, District
f  Columbia; NREVSS, National Respiratory and Enteric Virus Surveillance System;
CR, polymerase chain reaction; PR, Puerto Rico; RSV, respiratory syncytial virus;
I,  virus isolation.
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1. Background
Respiratory syncytial virus (RSV) circulates throughout the
United States in the fall through spring with variable onset, peak
month of activity, and season duration [1,2]. RSV surveillance data
are reported from multiple sources, including the US Centers for
Disease Control and Prevention (CDC), public health departments,
and university-based medical centers. For RSV, the CDC collects
and reports surveillance data regarding respiratory viruses through
the National Respiratory and Enteric Virus Surveillance System
(NREVSS), a national, laboratory-based passive surveillance system
[3,4].
Testing for RSV can be performed using any of 3 types of labo-
ratory diagnostic tests: (1) antigen detection; (2) polymerase chain
reaction (PCR); and (3) culture (virus isolation [VI]). Antigen detec-
tion tests are the most common diagnostic assays used to detect
RSV based on their low cost, ease of use, and rapid availability of
results [5,6]. Published reports from the CDC NREVSS describing
the RSV season (e.g., onset, offset, duration) are based only on anti-
gen detection results, and recent reports indicate that 94–98% of
reserved.
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Table 1
Characteristics of the RSVAlert® program (September 2007–August 2011).
Data collection period Laboratories, n States participating, n Test types collected
9/8/2007 to 8/30/2008 626 50 (+DC) Antigen, PCR, VI
9/6/2008 to 8/29/2009 666 50 (+DC) Antigen, PCR, VI
9/5/2009 to 5/1/2010a 647/296b 50 (+DC) Antigen, PCR, VI
8/14/2010 to 8/6/2011 480 50 (+DC, PR) Antigen, PCR, VI
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oC, District of Columbia; PCR, polymerase chain reaction; PR, Puerto Rico; RSV, resp
a Data were not collected from May  2010 to August 2010.
b Reduced laboratory site counts reﬂect program reduction beginning January 20
aboratories participating in this system use antigen detection as
he primary method for diagnosis of RSV [4,7]. Recent studies have
emonstrated the utility and increased sensitivity of PCR tests for
he detection of respiratory viruses [8,9]. The frequency of PCR use
o diagnose respiratory infections [10,11] in US hospital laborato-
ies has not been well described.
. Objectives
The objective of this analysis was to describe recent changes
ver time in the type of tests used for primary RSV detection by US
ospital laboratories, with a focus on the use of PCR.
. Study design
The RSVAlert® Program is a surveillance system designed to col-
ect and characterize RSV test data in a near real-time reporting
ystem at local, state, regional, and national levels [12].
Guiding recruitment characteristics for laboratories participat-
ng in RSVAlert® were: membership in the National Association
f Children’s Hospitals and Related Institutions, association with a
arge children’s and/or metropolitan hospital that contains a neona-
al and/or pediatric intensive care unit, high volume of RSV tests
eported in prior years (≥10 tests per week during RSV peak season)
12], and good reporting compliance (i.e., at least 70%) in prior years.
eographic representation across states and local community areas
as also considered during the annual recruiting process.
Data were collected from participating sites in all 50 states, the
istrict of Columbia, and Puerto Rico (2010–2011 season only).
esting and laboratory methods used were based on individ-
al institutional protocols and physician ordering practices. No
ttempt was made to standardize choice of patients tested or type
f test performed by each reporting laboratory. Test data were
eported within 14 days of the period stated; updates to weekly
est data were accepted.
Participating laboratories reported weekly to provide data
egarding the total number and results of diagnostic RSV tests
y the type of test performed (i.e., antigen detection, PCR, or VI),
nd results of all tests performed [12]. Antigen-based detection
ncluded all methodologies used at the time of data collection,
ncluding immunochromatography and direct immunoﬂuores-
ence; use was not stratiﬁed by test type. Absence of testing was
lso collected. Only primary test types and results were to be
eported in cases where both primary and conﬁrmatory tests were
erformed.
To describe clinical laboratory RSV testing trends, an analysis
as conducted using a convenience sample of RSV test data. Anal-
sis was limited to data reported during the months of November
hrough April to provide a standard review period and enable sub-
equent comparisons with the CDC’s seasonal data reporting. Data
ere aggregated weekly; each review period had a mean of 7 days.
To examine trends in the types of tests used, weekly propor-
ions of each test type were calculated, averaged across the week
n each review period, and reported as the mean weekly proportion
f each test type. Kendall  rank correlation was used to quantifyy syncytial virus; VI, virus isolation.
associations between time (i.e., seasonal weeks from November
2007 through April 2011) and the proportion of each test type (i.e.,
weekly contribution of primary screening results from each test
type from November 2007 through April 2011). The proportion
of laboratories using PCR tests during each season of the review
period was  also analyzed. To control for sample bias, a secondary
trend analysis was conducted using only the 220 laboratories that
consistently participated during all 4 seasons.
4. Results
The number of laboratories participating each season ranged
from 480 to 666 (Table 1). From January to May  2010, only 296
laboratories participated due to a program reduction. Antigen
detection was  the predominant test type reported during each
of the 4 seasons (Table 2). The weekly proportion of RSV tests
conducted using PCR increased signiﬁcantly from November
2007 through April 2011, (101) = 0.77, P < 0.0001. Conversely,
the weekly proportions of RSV tests conducted through antigen
detection and virus culture methods decreased during the same
period, (101) = −0.60, P < 0.0001, and (101) = −0.38, P < 0.0001,
respectively. The proportion of participating laboratories reporting
≥1 RSV test result using PCR increased from 4% in 2007–2008
to 16% in 2010–2011 (Table 2). The largest increases occurred
between the 2008–2009 and 2010–2011 RSV seasons. During
the review period, the proportion of laboratories using PCR
tests also increased over time (Fig. 1A). Similar temporal trends
were observed when data were analyzed for the subset of 220
consistently participating laboratories (Table 2, Fig. 1B).
5. Discussion
Although antigen detection remains the predominant test used
for the detection of RSV in US hospital laboratories, the use of
PCR has increased steadily over recent years. The proportion of
tests conducted and the number of laboratories reporting ≥1 PCR
tests increased each season. The largest increases were observed
between 2009 and 2011.
A number of factors may  have inﬂuenced the increased use
of PCR tests for RSV detection. Multiplex PCR tests that include
detection for RSV were ﬁrst approved by the US  Food and Drug
Administration in January 2008 [13]. Additionally, the fact that the
ﬁrst available test for 2009 H1N1 inﬂuenza was a CDC-developed
PCR test [14] may  also have encouraged institutions to adopt PCR
technology.
The results of this study are subject to several limitations.
Laboratory recruitment for the RSVAlert® program is focused on
children’s hospitals and large metropolitan hospitals. This sampling
method may  overrepresent pediatric and/or urban populations as
well as laboratories that routinely use PCR testing methods for RSV
screening. These sites may  differ from the total population because
of their commitment to disease surveillance and/or their ability to
commit resources to the reporting process. Also, a small proportion
(1% in the 2010–2011 season) of RSVAlert® laboratories was unable
to differentiate primary RSV tests from conﬁrmatory tests due to
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Table 2
Summary statistics for participating laboratories reporting RSV tests through RSVAlert® , November 2007–April 2011 data review period.a
2007–2008 2008–2009 2009–2010 2010–2011
All participating laboratories
Total reported tests, N 481,654 455,907 381,068 446,235
Mean weekly proportion: antigen detection, % 79 80 68 65
Mean weekly proportion: PCR, % 2 3 16 21
Mean weekly proportion: culture/virus isolation, % 19 16 16 14
Laboratories that reported ≥1 PCR test, n/N, % 25/626 (4) 36/666 (5) 62/647 (10) 76/480 (16)
Laboratories consistently participating in all 4 seasons
Total reported tests, N 266,302 255,230 274,981 292,878
Mean weekly proportion: antigen detection, % 80 80 69 64
Mean weekly proportion: PCR, % 2 4 16 22
Mean weekly proportion: culture/virus isolation, % 18 16 15 14
Laboratories that reported ≥1 PCR test, n/N (%) 15/220 (7) 24/220 (11) 42/220 (19) 51/220 (23)
PCR, polymerase chain reaction; RSV, respiratory syncytial virus.
a Data aggregated by week ending on Saturday.
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sig. 1. (A) Proportion of all participating laboratories using PCR tests. (B) Proportion
f  consistently reporting laboratories using PCR tests (n = 220). PCR, polymerase
hain reaction; RSV, respiratory syncytial virus.
he nature of their data processing systems. However, all other sites
rovided primary results exclusively.
. Conclusions
The results of the current analysis indicate that antigen detec-
ion remains the most frequent primary diagnostic method for RSV
esting within US hospital laboratories. However, the relative con-
ribution of PCR use increased over the 4 years studied to >20% of
otal primary tests reported.The uptake of PCR testing observed in this study is consistent
ith the increased use of diagnostic tests with improved sensi-
ivity and speciﬁcity in clinical and research settings [8,9,11]. This
uggests that the use of PCR tests in US hospital laboratories isincreasing. Healthcare providers should be familiar with local test-
ing patterns and institution testing protocols when evaluating RSV
surveillance data. Surveillance systems that rely solely on results of
antigen-based diagnostic tests will miss an increasing proportion
of RSV test results.
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